Paul Bernstein, MD
Ophthalmology · Salt Lake City, UTNPI 1023108651
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,710 of the $6,707 with a category attached, or 70.2%. Genentech USA, Inc. accounts for 77.7% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $2,590 and has fallen 82.5% since, to $454 in 2025.
Across 34 payments — averaging $197.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- Neurotech Pharmaceuticals, Inc.$256
- Regeneron Healthcare Solutions, Inc.$231
- Heidelberg Engineering, Inc.$219
- Oculus Surgical Inc.$162
- AbbVie$125
- plus $502 from 8 others
Across 44 payments — averaging $7902.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Apellis Pharmaceuticals, Inc.$200K
- Janssen Research & Development, LLC$76K
- Biogen$69K
- AbbVie$2K
What the payments were for
- Consulting fees$4,71070%
- Food & beverage$1,99730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 13 | $5,212 |
| Neurotech Pharmaceuticals, Inc. | 2 | $256 |
| Regeneron Healthcare Solutions, Inc. | 2 | $231 |
| Heidelberg Engineering, Inc. | 2 | $219 |
| Oculus Surgical Inc. | 1 | $162 |
| AbbVie(2 entities) | 5 | $125 |
| Novartis | 1 | $102 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $93 |
| Alimera Sciences, Inc. | 1 | $92 |
| Eyepoint US, Inc. | 2 | $74 |
| Dutch Ophthalmic, USA | 1 | $51 |
| Apellis Pharmaceuticals, Inc. | 1 | $37 |
| Genentech, Inc. | 1 | $29 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lucentis$4,710
- SUSVIMO$260
- Spectralis$200
- EYLEA HD$120
- EYLEA$111
How this compares
$6,707 in reported general payments places this provider in the 85th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $179 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Salt Lake City
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Douglas MarxSalt Lake City$22K
- Akbar ShakoorSalt Lake City$18K
- Craig ChayaSalt Lake City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.